It is important to note that the first dose level (50 mill cells) is 11% of the final dose escalation level (450 mill cells).
If CDH17 kills the tumour at the lowest dose level (which was more about minimising the risk of toxicity to the first patients), then imagine what the efficacy will be like if we increase the dose by 9 times!!
- Forums
- ASX - By Stock
- CHM
- CDH17 Phase 1/2 trial
CHM
chimeric therapeutics limited
Add to My Watchlist
0.00%
!
0.3¢

CDH17 Phase 1/2 trial, page-9
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.323M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.3¢ | $26.66K | 8.722M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
72 | 71177716 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 94220096 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
70 | 70544383 | 0.003 |
28 | 29246484 | 0.002 |
12 | 52464000 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 94220096 | 28 |
0.005 | 33548062 | 22 |
0.006 | 15179018 | 19 |
0.007 | 6904829 | 8 |
0.008 | 7317101 | 5 |
Last trade - 14.10pm 28/07/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |